Human Gut Microbiota and microRNA Expression

NCT ID: NCT05392348

Last Updated: 2022-05-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

36 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-05-25

Study Completion Date

2022-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this study, stachyose was used as an intervention factor. We will evaluate changes in fecal gut microbiota and miRNA expression profiles in subjects under stachyose intervention

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In the stachyose intervention group, each person in the stachyose intervention group took 5 g of stachyose daily before breakfast, and the administration method was 100 ml of drinking water dissolved and taken orally for two months. Each person in the placebo control group took the same amount of maltodextrin daily. Stool samples of the subjects were collected weekly.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gut Microbiota microRNA

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Normal Control group

Subjects with maltodextrin as intervention,5g/kg·bw/day.

Group Type PLACEBO_COMPARATOR

Maltodextrin

Intervention Type DIETARY_SUPPLEMENT

Maltodextrin is a polysaccharide that is used primarily in foods and beverages as a thickener, sweetener, and/or stabilizer. It is a relatively short-chain polymer (some would call it an oligomer); commercial products contain an average of ≈3 to ≈17 glucose units per chain. It is manufactured by partially hydrolyzing grain starches, usually corn or wheat.

Stachyose intervention group

Subjects with stachyose as intervention,5g/kg·bw/day.

Group Type EXPERIMENTAL

stachyose

Intervention Type DIETARY_SUPPLEMENT

Stachyose is a tetrasaccharide consisting of sucrose having an alpha-D-galactosyl-(1-\>6)-alpha-D-galactosyl moiety attached at the 6-position of the glucose.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

stachyose

Stachyose is a tetrasaccharide consisting of sucrose having an alpha-D-galactosyl-(1-\>6)-alpha-D-galactosyl moiety attached at the 6-position of the glucose.

Intervention Type DIETARY_SUPPLEMENT

Maltodextrin

Maltodextrin is a polysaccharide that is used primarily in foods and beverages as a thickener, sweetener, and/or stabilizer. It is a relatively short-chain polymer (some would call it an oligomer); commercial products contain an average of ≈3 to ≈17 glucose units per chain. It is manufactured by partially hydrolyzing grain starches, usually corn or wheat.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* healthy human

Exclusion Criteria

* people who need intake antibiotics,probiotics or its product
Minimum Eligible Age

18 Years

Maximum Eligible Age

30 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Xijing Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Chao Guo

Role: STUDY_CHAIR

Xijing Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

the First Affiliate Hospital of the Air Force Medical University

Xi'an, Shaanxi, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Chao Guo

Role: CONTACT

029-84775475 ext. 8203

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Ting Li, PhD

Role: primary

15891720780

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

KY20212094-C-1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.